TY - JOUR
KW - Amphetamine-Related Disorders/therapy
KW - Central Nervous System Stimulants/adverse effects/economics/therapeutic use
KW - cognitive behavioral therapy
KW - Cost-Benefit Analysis
KW - Double-Blind Method
KW - Humans
KW - Lisdexamfetamine Dimesylate/adverse effects/economics/therapeutic use
KW - Methamphetamine
KW - Randomized Controlled Trials as Topic
KW - Self Report
KW - Substance Abuse Detection
KW - Urinalysis
KW - lisdexamfetamine
KW - pharmacotherapy
KW - stimulant use disorder
KW - study protocol
AU - N. Ezard
AU - A. Dunlop
AU - M. Hall
AU - R. Ali
AU - R. McKetin
AU - R. Bruno
AU - N. Phung
AU - A. Carr
AU - J. White
AU - B. Clifford
AU - Z. Liu
AU - M. Shanahan
AU - K. Dolan
AU - A. L. Baker
AU - N. Lintzeris
A1 - 
AD - Alcohol and Drug Service, St Vincents Hospital, Sydney, New South Wales, Australia.; University of New South Wales, Randwick, New South Wales, Australia.; Drug and Alcohol Clinical Services, Hunter New England, Newcastle, New South Wales, Australia.; School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.; Drug and Alcohol Clinical Services, Hunter New England, Newcastle, New South Wales, Australia.; University of New South Wales, Randwick, New South Wales, Australia.; University of Adelaide, Adelaide, South Australia, Australia.; Curtin University, Perth, Western Australia, Australia.; University of South Australia, Adelaide, South Australia, Australia.; University of Tasmania, Hobart, Tasmania, Australia.; Western Sydney Local Health District, Sydney, New South Wales, Australia.; Alcohol and Drug Service, St Vincents Hospital, Sydney, New South Wales, Australia.; University of New South Wales, Randwick, New South Wales, Australia.; University of South Australia, Adelaide, South Australia, Australia.; Alcohol and Drug Service, St Vincents Hospital, Sydney, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia.; University of New South Wales, Randwick, New South Wales, Australia.; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.; School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.; University of Sydney, Sydney, New South Wales, Australia.; South East Sydney Local Health District, Sydney, New South Wales, Australia.
BT - BMJ open
C5 - Financing & Sustainability; Opioids & Substance Use
CP - 7
DO - 10.1136/bmjopen-2017-020723
IS - 7
JF - BMJ open
LA - eng
M1 - Journal Article
PB - . Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ
PY - 2018
SN - 2044-6055; 2044-6055
SP - 2017
EP - 020723
EP - e020723+
T1 - LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence
T2 - BMJ open
TI - LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence
U1 - Financing & Sustainability; Opioids & Substance Use
U2 - 30030312
U3 - 10.1136/bmjopen-2017-020723
VL - 8
VO - 2044-6055; 2044-6055
Y1 - 2018
Y2 - Jul 19
ER -